Statement of Principles concerning pure red cell aplasia (Balance of Probabilities) (No. 61 of 2020)

The central concept is “pure red cell aplasia” as defined in section 7(2). It means complete or nearly complete cessation of red cell production in the bone marrow without affecting other haematopoietic cells, characterised by anaemia, reticulocytopaenia, and absent or rare erythroid precursor cells in the bone marrow. The definition expressly excludes congenital Diamond‑Blackfan anaemia, myelodysplastic syndrome, and paroxysmal nocturnal haemoglobinuria. A claimant who actually suffers one of those exclusions cannot rely on this SoP, even if their condition otherwise resembles PRCA. The ICD‑10‑AM code D60 is assigned but is only a reference; the clinical definition in the instrument governs. The SoP also defines “death from pure red cell aplasia” to include death contributed to by PRCA through a terminal event such as pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function (Schedule 1). This means the disease need not be the sole cause; it is enough that PRCA contributed to the chain of events.

The key mechanism is the list of ten factors that must exist (section 9). These are: (1) pregnancy at clinical onset; (2) treatment with a drug specified in Schedule 2 within six months before onset; (3) treatment with a drug (not necessarily in Schedule 2) that is individually associated with both onset within six months and improvement within six months of discontinuing or tapering; (4) benzene exposure as specified (cutaneous, ingestion, or inhalation at >5 ppm 8‑hour TWA) on at least 45 days within six months before onset; (5) acute hepatitis within one year before onset; (6) liver transplant within three months before onset; (7) an autoimmune disease from a narrow specified list within two years before onset; (8) chronic lymphocytic leukaemia/small lymphocytic lymphoma or T‑cell large granular lymphocytic leukaemia within six months before onset; (9) a thymoma or thymic carcinoma at any time before onset; (10) parvovirus B19 infection within six months before onset; (11) pregnancy at the time of clinical worsening; (12) inability to obtain appropriate clinical management for PRCA. Factors (11) and (12) apply only to material contribution or aggravation of pre‑existing PRCA, not to initial causation (section 10(2)). The factor must be related to the person’s relevant service; the Service itself need not have caused the factor directly, but the factor must have occurred during or as a consequence of service. For example, if a veteran developed an autoimmune disease while in service, and that disease is on the specified list (systemic lupus erythematosus, graft versus host disease, etc.), then the PRCA onset can be linked. The specified list of autoimmune diseases is notably short: only six conditions (Schedule 1). Common autoimmune diseases such as rheumatoid arthritis or type 1 diabetes are not included. This means that a veteran with PRCA and a history of rheumatoid arthritis cannot rely on factor (7). The drug list in Schedule 2 is broad, covering alkylating agents, allopurinol, antimetabolites, azathioprine, carbamazepine, carbonic anhydrase inhibitors, chloramphenicol, dapsone, d‑penicillamine, gold, hydantoins, immune checkpoint inhibitors, isoniazid, lamivudine, linezolid, mycophenolate, phenytoin, procainamide, recombinant erythropoietin, sulphonamide antibiotics and their derivatives, sulphonylureas, valproic acid, and zidovudine. Notably, many of these drugs are used in chemotherapy (alkylating agents, antimetabolites), immunosuppression (azathioprine, mycophenolate), anti‑infection (chloramphenicol, isoniazid, sulphonamides) and neurology (carbamazepine, valproic acid, phenytoin). The inclusion of recombinant erythropoietin is significant because that drug is itself used to treat anaemia, yet it can paradoxically trigger PRCA via antibody formation. Factor (3) is an alternative for drugs not on the list but for which there is individual evidence of causation and reversibility; this is a safety valve for idiosyncratic drug reactions.

The SoP directly affects veterans and members of the Australian Defence Force who have rendered “relevant service” as defined in Schedule 1. Relevant service under the VEA means eligible war service (other than operational service) and defence service (other than hazardous service and British nuclear test defence service). Under the MRCA, it means peacetime service. This excludes veterans who had operational service (e.g., in a war‑like theatre) or hazardous service - they would fall under a different SoP made under subsection 196B(2) (reasonable hypothesis). The SoP thus governs claims for those whose service is domestic or non‑combat, where the standard of proof is balance of probabilities. That includes Defence Force members who served only in peacetime within Australia, reservists on non‑operational duties, and veterans whose war service was not operational (e.g., some home‑front roles). The instrument also affects widows, widowers, and dependants claiming in respect of a death from PRCA, because the definition of death includes contribution through terminal events. Medical practitioners and specialists are indirectly affected because their reports must address the specific factors: they need to comment on whether the veteran was pregnant, took a listed drug, had the specified autoimmune disease, had a thymoma, etc., and the temporal relationship to the clinical onset. Decision‑makers in the Department of Veterans’ Affairs and the Military Rehabilitation and Compensation Commission are bound to apply the SoP when assessing claims. The instrument narrows the range of acceptable evidence: for example, a general opinion that “the PRCA might be due to service” is insufficient unless it connects to one of the 12 factors. Legal representatives and advocates must help claimants identify which factor applies and then obtain medical evidence tailored to the SoP’s wording. The specified list of autoimmune diseases is so limited that a veteran with an autoimmune disease not listed (e.g., multiple sclerosis, Hashimoto’s thyroiditis) cannot use that pathway, even if the disease plausibly contributed to PRCA. This creates a group of claimants who may have sound medical causation but no legal route under this SoP - they would need to argue general causation outside the SoP or wait for the Authority to update the list. The pharmaceutical industry may be affected because the drug list raises the risk of litigation by implication (though the SoP itself does not create liability). The benzene exposure definition affects employers and military training establishments where benzene may have been used (fuel, solvents, degreasers). The requirement of 45 days exposure within six months before onset means that brief or low‑level exposure cannot be used.

The SoP does not impose duties on private individuals. It imposes a duty on the decision‑maker (the Repatriation Commission or the Military Rehabilitation and Compensation Commission) to apply the factors when determining whether PRCA is connected to service. The claimant has the right to have their claim assessed using this SoP if the claim is for non‑operational or peacetime service. The claimant also has the right to lead evidence that one of the factors exists. If the decision‑maker refuses to accept that a factor is established, the claimant has the right to seek merits review by the Veterans’ Review Board and, ultimately, judicial review. However, the SoP itself restricts the decision‑maker’s discretion: if a factor is found to exist and is related to service, the decision‑maker must find that the disease is connected on the balance of probabilities. Conversely, if no factor exists, the decision‑maker must find that the disease is not connected, unless the claimant can prove causation through other medical‑scientific evidence that overcomes the presumption - which is difficult given the Authority’s declaration that the factors are based on “sound medical‑scientific evidence” (section 8). The claimant thus has an evidential right to rely on the factors, but also an evidential burden to demonstrate them. Factor (12) “inability to obtain appropriate clinical management for pure red cell aplasia” is unique: it applies only to aggravation (section 10(2)). This implies that a veteran whose PRCA worsened because they could not get proper treatment while in service (e.g., due to postings, unsanitary conditions, or lack of specialist care) can claim that the worsening is service‑related. The right is conditional on the prior existence of PRCA (contracted before or during but not arising out of service). The duty on the Commission is fairly to consider all medical evidence, including evidence that a drug not listed in Schedule 2 but meeting factor (3) individually applies. The Commission must also consider whether a factor is “related to the relevant service” - section 10(1) means the factor must have been incurred during service or due to service. For example, if a veteran was exposed to benzene in civilian employment but not during service, the factor does not count, even if the exposure was before onset. The instrument thus creates a closed list of causation pathways; any novel theory is not permitted unless it fits within the definitions. The right to be assessed under the correct SoP version is also important: the repeal of the 2012 aplastic anaemia SoP means that any claim for PRCA cannot be assessed under that now‑repealed instrument. However, a claim for aplastic anaemia (a different disease) would still have its own SoP (if one exists). The instrument is dated 28 August 2020 and commences 28 September 2020; claims determined before that date were subject to the earlier SoP or general law.

This SoP contains no penalty provisions. It is not a criminal or civil penalty instrument. The “enforcement” in this context is administrative: the Repatriation Commission must apply the SoP when making decisions on claims for disability pension or compensation. Failure to apply the SoP correctly could lead to a wrong decision, which the claimant can challenge through merits review or judicial review. There are no fines, imprisonment, or infringement notices in the instrument. However, there is an indirect penalty: a veteran who is improperly denied a claim because the decision‑maker misapplied the SoP will suffer a loss of benefits. The decision‑maker could be directed by the Veterans’ Review Board or the Administrative Appeals Tribunal to reconsider the claim applying the correct SoP. Under the VEA, the Commission can be compelled to pay arrears and costs. There is no private right of action against the Commonwealth for breach of the SoP itself; the remedy is through the statutory claims process. If a claimant fraudulently asserts a factor that does not exist (e.g., lying about pregnancy or drug use), that could constitute an offence under the Criminal Code (e.g., obtaining a financial advantage by deception) but the SoP does not create that. The Authority itself faces no penalty if the SoP is later found to be flawed - the instrument can be amended or repealed. The enforcement of the SoP is thus entirely through the decision‑making hierarchy and the review system. The instrument does contain a provision that if a factor refers to another disease covered by a different SoP, that other SoP applies (section 11). This means that if factor (8) requires having chronic lymphocytic leukaemia, and the veteran has that leukaemia, the Commission must also apply the SoP for that leukaemia to determine if it is service‑related. This cross‑referencing creates a cascade of liability that the decision‑maker must enforce correctly. The practical enforcement risk is that decision‑makers may incorrectly limit the factors, for example by requiring that the specified drug be taken for a minimum duration even though the SoP does not state one. That would be an error of law and could be overturned on review.

The SoP is made under section 196B(3) of the Veterans’ Entitlements Act 1986, which is itself a Commonwealth Act. The VEA coexists with the Military Rehabilitation and Compensation Act 2004 (MRCA) and the Safety, Rehabilitation and Compensation (Defence‑related Claims) Act 1988 (DRCA). The SoP explicitly applies to claims under section 120B of the VEA (for non‑operational service) and section 339 of the MRCA (for peacetime service). It does not apply to claims under the DRCA because that Act has its own causation framework, though the SoP may be used as evidence. The instrument also interacts with the Social Security Act 1991 indirectly: a veteran’s disability pension received under the VEA can affect other benefits, but the SoP itself is not a social security law. The definition of pure red cell aplasia uses the ICD‑10‑AM coding system, which is a classification standard used by hospitals and health insurers. However, the instrument stresses that the clinical definition overrides the code (section 7(3)). This means that a diagnosis based purely on a billing code without the bone marrow findings would not satisfy the definition. The SoP also interacts with the Therapeutic Goods Act 1989: the specified drugs in Schedule 2 are generally prescription medicines, but the instrument does not regulate them; it merely treats them as potential causal agents. There is an indirect interaction with the Fair Work Act 2009 if a veteran’s PRCA arose from work‑related factors, but the SoP does not provide a cause of action against an employer. The instrument also interacts with the Repatriation Medical Authority’s own other SoPs: section 11 ensures that if a factor refers to another disease (e.g., systemic lupus erythematosus), the SoP for that disease must be used to assess whether that disease is service‑related. This prevents decision‑makers from finding a factor exists without verifying the underlying disease’s connection to service. The repeal of the earlier aplastic anaemia SoP (No. 51 of 2012) ends any cross‑reference to that SoP; note that the 2012 SoP covered aplastic anaemia, not pure red cell aplasia, so the repeal is slightly odd - perhaps the Authority considered that the 2012 SoP had been used erroneously for PRCA. In any event, the 2020 SoP stands alone. The instrument does not override state workers’ compensation laws; it only applies to federal veterans and defence compensation schemes.

The instrument itself is the primary amendment event: it repeals the “Statement of Principles concerning aplastic anaemia No. 51 of 2012 (Federal Register of Legislation No. F2012L01793)” and replaces it with this pure red cell aplasia SoP. There is no other amendment history within the source. The instrument was made on 28 August 2020 and commences on 28 September 2020. The repealed SoP was for a different disease (aplastic anaemia), so this is not a direct replacement but a new SoP for PRCA. The Authority likely determined that a specific SoP for PRCA was warranted given that PRCA is a distinct haematological condition. The amendment history after 2020 is not provided; subsequent amendments to this SoP (if any) would have to be searched separately. The instrument does not mention any transitional provisions; however, the application clause (section 5) says it applies to claims to which sections 120B VEA or 339 MRCA apply. That suggests it applies to claims made on or after the commencement date, and possibly to pending claims that have not been finally determined, depending on standard transitional rules in the VEA. The repeal of the 2012 SoP means that no claim for pure red cell aplasia can be assessed under that old instrument after 28 September 2020. If a claim was lodged before that date but not yet decided, the decision‑maker would likely use the new instrument because it is the current statement of principles - but the VEA may require using the instrument in force at the time of the claim. The note in the source does not resolve that. There is no indication of any amendment to the VEA itself that this SoP implements.

The source text contains no reference to any litigation. However, it is well known that Statements of Principles under the VEA are frequently challenged in the Federal Court and the High Court on grounds such as whether the Authority considered all sound medical‑scientific evidence, whether the factors are arbitrary, or whether the instrument complies with the VEA. For example, cases such as Repatriation Commission v Gorton (2001) and others have considered the validity of SoPs. Since this SoP was made in 2020, any litigation specifically concerning it would need to be found through a separate search. The instrument itself does not mention any cases. Given the subject matter, likely litigation would arise from veterans who are unable to satisfy a factor despite having plausible causation (e.g., from an autoimmune disease not on the specified list). The definition of pure red cell aplasia might be contested if a medical expert says the claimant has a congenital form (excluded) but the veteran argues it is acquired. The benzene exposure factor might be litigated on what constitutes “cutting” or “ingesting” liquids containing benzene greater than 1% by volume. The temporal windows (six months, one year, two years, three months) are precise and could be challenged as not reflecting the sound medical‑scientific evidence. However, the Authority has broad discretion and courts give deference to its specialised judgment. This SoP has not been the subject of any cited case in the source.

Several traps for the unwary exist in this instrument. First, the definition of pure red cell aplasia excludes three important conditions: congenital Diamond‑Blackfan anaemia, myelodysplastic syndrome, and paroxysmal nocturnal haemoglobinuria. Any veteran diagnosed with one of those will be denied under this SoP even if their clinical presentation is similar. Second, the specified list of autoimmune diseases is very short - only six items, and two of them are transplants (ABO mismatched haematopoietic stem cell transplant and graft versus host disease). A veteran with common autoimmune diseases such as rheumatoid arthritis, Hashimoto’s thyroiditis, type 1 diabetes, or coeliac disease cannot use factor (7). That means that even if a medical specialist opines that a different autoimmune disease caused the PRCA, the SoP does not recognise it. Third, the benzene exposure factor requires a minimum of 45 days exposure within six months before onset, and the exposure must be to benzene at concentrations greater than 5 parts per million (8‑hour TWA). Many fuel exposures are below that level, and one‑off spills cannot be aggregated if they do not reach the 45‑day threshold. Fourth, factor (3) - drug not in Schedule 2 - is often overlooked. It requires that the individual shows both development of PRCA within six months of starting the drug and improvement within six months of discontinuing or tapering. This is a high bar: it demands evidence of a temporal relationship in both directions. A doctor’s unsupported opinion that a drug “might” cause PRCA is insufficient. Fifth, the instrument applies only to relevant service as defined. If a veteran has some operational service and some peacetime service, the decision‑maker must apply the correct SoP for each claim component. This SoP cannot be used for a claim based on operational service. Sixth, the “clinical worsening” factors (11 and 12) apply only to aggravation claims, not to initial causation. That means a veteran whose PRCA was not service‑related in origin but worsened during service must still prove that the worsening was due to pregnancy or inability to obtain appropriate clinical management. Notably, factor (12) “inability to obtain appropriate clinical management” sounds promising but is restricted to aggravation only, and the term “appropriate clinical management” is not defined - it may be narrowly interpreted by tribunals. Seventh, the drug list in Schedule 2 includes “recombinant erythropoietin” which is ironic because that drug is used to treat anaemia and can itself cause PRCA. A veteran who took erythropoietin for kidney disease and then developed PRCA may have a claim, but only if the other timing requirements are met. Eighth, the definition of death from PRCA includes terminal events such as pneumonia. This means that if a veteran dies from pneumonia, and PRCA contributed to the pneumonia (e.g., through immunosuppression), the death claim may succeed even if PRCA was not the immediate cause. But the pneumonia must be contributed to by PRCA, not just coincident.

For a claimant or their representative, the first step is to confirm the diagnosis meets the definition - that is, complete or nearly complete cessation of red cell production with no other cell line suppression, and excludes the three named conditions. A bone marrow biopsy report is essential to show absent or rare erythroid precursors and normal myeloid and megakaryocytic lineages. Next, identify the date of clinical onset. Then, run through each factor in section 9 and gather evidence for the most plausible one. For factor (2), obtain a list of all medications taken within six months before onset and check against Schedule 2. If a drug is on the list, the medical records must show treatment within that window. No minimum duration of treatment is specified - a single dose could theoretically be enough, though clinical plausibility matters. For factor (3), if the drug is not on the list, find evidence of a clear temporal pattern: onset soon after starting the drug and improvement soon after stopping. That may require serial blood counts around the time of drug changes. For factor (4), benzene exposure: service records may show duties involving fuel handling, degreasing, or lab work. For each such exposure, estimate the benzene concentration. The SoP requires exceeding 5 ppm 8‑hour TWA, which is relatively high - typical modern occupational limits are 1 ppm. Older service records might show higher exposures. Count the number of days of such exposure within the six months before onset; must be at least 45 days. For factor (5), acute hepatitis: obtain liver function tests and hepatitis serology within one year before onset. For factor (6), liver transplant: confirm the date of transplant was within three months before onset. For factor (7), autoimmune disease: confirm the diagnosis is on the very short specified list. For factor (8), leukaemia: obtain haematology reports showing CLL/SLL or T‑LGL leukaemia within six months before onset. For factor (9), thymoma or thymic carcinoma: imaging (CT chest) reports from any time before onset. For factor (10), parvovirus B19 infection: serology (IgM positive) or PCR in the six months prior. For aggravation factors (11) and (12), the veteran must have had PRCA before service or before the relevant period, and then show that pregnancy or inability to get appropriate management made it worse. The ‘inability’ factor might require evidence of barriers to treatment (e.g., being on a ship without access to a haematologist, or delays in diagnosis due to military medical system). Document the service‑related cause of that inability. Once the factor is identified, ensure it is “related to the relevant service”. That means the factor itself must have occurred during service or due to service. For example, if a veteran took a specified drug for a civilian illness before enlisting, that factor does not count. But if the drug was prescribed by a defence force doctor, it counts. Prepare a statement of service history connecting the factor. Provide medical reports that explicitly state the temporal relationships and use the language of the SoP. Avoid general statements. The decision‑maker will apply the SoP strictly; if the medical evidence does not match the exact wording (e.g., “six months before clinical onset” not “around that time”), the claim will fail. It may also be prudent to consider whether a factor refers to another disease covered by a different SoP (section 11). For example, if factor (7) graft versus host disease is present, the decision‑maker must apply the SoP for GVHD to check if that is service‑related. Provide evidence for that underlying disease as well. Finally, if no factor applies, the claim can still be argued on general grounds, but the SoP’s declaration that the factors are based on sound medical‑scientific evidence makes it difficult to overcome. The better strategy is to look carefully at factor (3) which is broader than the fixed list.